

KHIRON LIFE SCIENCES FACTSHEET

OVERVIEW

\$13M
CAD
2021
Total Revenue

- **4.6M** MCAD medical cannabis revenues in 2021
- **30%** European cannabis sales in 2021
- **73%** gross margins in medical cannabis sales in 2021
- **~4.5M** MCAD total revenue for Q1 2022
- **~2.5M** MCAD medical cannabis revenues in Q1 2022
- **▲50%** cannabis revenues generated in Europe in Q1 2022

WHY KHIRON


- **Latin America** and **Europe** will be the world's next high-growth regions for medical cannabis (USA 5 years ago)
- Khiron is currently the **TOP selling brand in UK, Latin America**, and one of the fastest growing companies in Germany, poised to be the leader in these **7 MILLION PATIENT potential** markets
- Unique **B2C** model with very high and sustainable grow margins with double digit month on month growth over the past 18 months
- Execution and **first mover advantage** in some of the world's largest potential markets (**Mexico, Colombia, Brazil, UK**)
- Experienced and diverse team with successful execution record & ability to understand and lead the global cannabis market
- High gross profitability resulting in achievable cash flow neutrality within next 9 – 12 months

NON-STOP GROWTH IN EUROPE AND LATAM

Khiron Latin America

(Colombia, Peru, Brazil)


Sales Volume (Tincture Units @ 30ML / unit)



Khiron Europe

(UK, Germany)

Sell-Out Volume (dried cannabis in grams)




REVENUE DRIVERS

Revenue Mix 2021


± 13.0 Million CAD

- Medical Services
- Cannabis - Europe
- Cannabis - LatAm



Khiron Revenue Projections

CAD Millions



All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

CAPITAL STRUCTURE

Basic Shares Outs.	179 Million
F/D Shares Outs.	253 Million
Share Price (CAD)	CAD 0.25
Market Cap (basic)	CAD 45 Million

ANALYST COVERAGE	
	ATB
	0.8 CAD / s
	Research Corp 0.75
	CAD / s

Leader in high growth, high-profit markets in Latin America and Europe

Creating a "true brand", expanding customer base of returning patients

Creating unique data and evidence of increased prescriptions in our target markets

Clear short-term path to profitability

LATIN AMERICA & EUROPE: NEXT BIG WORLDWIDE MEDICAL CANNABIS MARKETS

Latin America

650 Million population



>8

Countries with approved medical cannabis laws

COLOMBIA

1st country with insurance coverage for medical cannabis

4.0

Million Potential Patients in LatAm by 2025 ¹



\$ 450

Annual Expenditure in Medical Cannabis in LatAm³

Europe

750 Million population



>20

Countries with approved medical cannabis laws

GERMANY

Full insurance coverage for medical cannabis

2.6

Million Potential Patients in Europe by 2025 ²



\$1,800

Annual Expenditure in Medical Cannabis in Europe ²

(1) Prohibition Partners - The Latin America and Caribbean Cannabis Report 2nd Edition
 (2) Prohibition Partners - The European Cannabis Report Edition 6th and management estimates
 (3) Management estimates



KHIRON IN EUROPE: Leveraging LatAm know-how to be a fast-growing company in the region

- One of the fastest growing medical cannabis companies in the region, operating in UK and Germany
- TOP medical cannabis brand in the UK
- The leading CBD-predominant cannabis flower in Germany

Khiron in the United Kingdom

Building a true brand with growing returning customers / clients

Khiron the UK
Increasing monthly spend with UK patients





KHIRON IN LATAM & COLOMBIA: Unique B2C approach to build the TOP cannabis brand

Khiron Colombia

Creating brand loyalty manifesting in higher retention rate

Khiron Colombia
Average monthly spend on medical cannabis per patient



- Vertical integration with its proprietary health centers and clinics focused on ensuring and providing access for patients to medical cannabis
- In 2021, Colombia becomes 1st country in Latin America to offer insurance coverage for medical cannabis to ALL patients

